Table 4.
Nuclear AR Expression in Prostate Cancer Stratified by ERG Status
| Cohort | Diagnosis/Recurrence status | Core # (ERG+/ERG-) | AR Mean OD ± SD | |
|---|---|---|---|---|
|
| ||||
| ERG+ | ERG- | |||
| pTMA | Benign Prostate | 0/84 | 0.19 ± 0.06 | |
| HGPIN | 30/25 | 0.27 ± 0.07 | 0.21 ± 0.07 | |
| PCa, local* | 41/40 | 0.30 ± 0.05* | 0.21 ± 0.08* | |
| PCa, aggressive | 35/26 | 0.26 ± 0.05 | 0.22 ± 0.04 | |
| Metastases | 18/23 | 0.33 ± 0.07 | 0.25 ± 0.16 | |
| oTMA | Benign Prostate | 0/72 | 0.19 ± 0.05 | |
| None* | 98/128 | 0.30 ± 0.05* | 0.25 ± 0.06* | |
| Biochemical | 31/44 | 0.28 ± 0.06 | 0.26 ± 0.06 | |
| Cancer | 14/25 | 0.30 ± 0.06 | 0.25 ± 0.05 | |
*
p < 0.001 ERG+ vs. ERG-;
ERG+ PCa = 51% in pTMA cohort, ERG+ PCa = 42% in oTMA cohort.